Aquaporin-2 in the early stages of the adenine-induced chronic kidney disease model.
Chronic kidney disease (CKD) is one of the leading health problems in the world. It is silent in the early stages and gradually progresses, inducing renal physiological and structural alterations. Moreover, CKD is associated with impaired life quality, increased risk for cardiovascular diseases, and...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0314827 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540208201990144 |
|---|---|
| author | Lucas H Oronel Maria Ortiz Carolina Yarza Sofía Gayone Carlos Davio Mónica Majowicz Maria Florencia Albertoni Borghese |
| author_facet | Lucas H Oronel Maria Ortiz Carolina Yarza Sofía Gayone Carlos Davio Mónica Majowicz Maria Florencia Albertoni Borghese |
| author_sort | Lucas H Oronel |
| collection | DOAJ |
| description | Chronic kidney disease (CKD) is one of the leading health problems in the world. It is silent in the early stages and gradually progresses, inducing renal physiological and structural alterations. Moreover, CKD is associated with impaired life quality, increased risk for cardiovascular diseases, and reduced life expectancy. Different CKD animal models differ in underlying etiology, time of onset, and associated diseases. The 0.25% adenine diet induces progressive kidney damage, constituting an adequate model mimicking human CKD. Vasopressin (VP) was postulated as a mediator of CKD, mainly acting through its V2 receptors. However, the molecular mechanisms involved in the pathogenesis of this condition and its progression still are not entirely understood. This study aimed to evaluate if AQP2 expression is altered in an adenine-induced model of CKD in rats at early stages of development (two weeks) and to assess a potential beneficial effect of Tolvaptan (a V2 receptor antagonist) treatment. We showed an increased renal medullary AQP2 expression at two weeks of adenine administration. This increase was mainly cytoplasmic, explaining the increased urinary volume of CKD rats and suggesting a possible non-canonical role for AQP2. In addition, Tolvaptan effectively inhibited the V2 receptor in both control and CKD rats, decreasing AQP2 expression and increasing diuresis. Moreover, Tolvaptan slightly reduced BUN and plasma creatinine. On the other hand, the renal alterations induced by adenine in CKD rats were not prevented by Tolvaptan. |
| format | Article |
| id | doaj-art-c21457f132ec461dad2966046bd94d38 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-c21457f132ec461dad2966046bd94d382025-02-05T05:31:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01201e031482710.1371/journal.pone.0314827Aquaporin-2 in the early stages of the adenine-induced chronic kidney disease model.Lucas H OronelMaria OrtizCarolina YarzaSofía GayoneCarlos DavioMónica MajowiczMaria Florencia Albertoni BorgheseChronic kidney disease (CKD) is one of the leading health problems in the world. It is silent in the early stages and gradually progresses, inducing renal physiological and structural alterations. Moreover, CKD is associated with impaired life quality, increased risk for cardiovascular diseases, and reduced life expectancy. Different CKD animal models differ in underlying etiology, time of onset, and associated diseases. The 0.25% adenine diet induces progressive kidney damage, constituting an adequate model mimicking human CKD. Vasopressin (VP) was postulated as a mediator of CKD, mainly acting through its V2 receptors. However, the molecular mechanisms involved in the pathogenesis of this condition and its progression still are not entirely understood. This study aimed to evaluate if AQP2 expression is altered in an adenine-induced model of CKD in rats at early stages of development (two weeks) and to assess a potential beneficial effect of Tolvaptan (a V2 receptor antagonist) treatment. We showed an increased renal medullary AQP2 expression at two weeks of adenine administration. This increase was mainly cytoplasmic, explaining the increased urinary volume of CKD rats and suggesting a possible non-canonical role for AQP2. In addition, Tolvaptan effectively inhibited the V2 receptor in both control and CKD rats, decreasing AQP2 expression and increasing diuresis. Moreover, Tolvaptan slightly reduced BUN and plasma creatinine. On the other hand, the renal alterations induced by adenine in CKD rats were not prevented by Tolvaptan.https://doi.org/10.1371/journal.pone.0314827 |
| spellingShingle | Lucas H Oronel Maria Ortiz Carolina Yarza Sofía Gayone Carlos Davio Mónica Majowicz Maria Florencia Albertoni Borghese Aquaporin-2 in the early stages of the adenine-induced chronic kidney disease model. PLoS ONE |
| title | Aquaporin-2 in the early stages of the adenine-induced chronic kidney disease model. |
| title_full | Aquaporin-2 in the early stages of the adenine-induced chronic kidney disease model. |
| title_fullStr | Aquaporin-2 in the early stages of the adenine-induced chronic kidney disease model. |
| title_full_unstemmed | Aquaporin-2 in the early stages of the adenine-induced chronic kidney disease model. |
| title_short | Aquaporin-2 in the early stages of the adenine-induced chronic kidney disease model. |
| title_sort | aquaporin 2 in the early stages of the adenine induced chronic kidney disease model |
| url | https://doi.org/10.1371/journal.pone.0314827 |
| work_keys_str_mv | AT lucashoronel aquaporin2intheearlystagesoftheadenineinducedchronickidneydiseasemodel AT mariaortiz aquaporin2intheearlystagesoftheadenineinducedchronickidneydiseasemodel AT carolinayarza aquaporin2intheearlystagesoftheadenineinducedchronickidneydiseasemodel AT sofiagayone aquaporin2intheearlystagesoftheadenineinducedchronickidneydiseasemodel AT carlosdavio aquaporin2intheearlystagesoftheadenineinducedchronickidneydiseasemodel AT monicamajowicz aquaporin2intheearlystagesoftheadenineinducedchronickidneydiseasemodel AT mariaflorenciaalbertoniborghese aquaporin2intheearlystagesoftheadenineinducedchronickidneydiseasemodel |